丁珍珍,王丽丽,闫锡钊,安凤兰,杨晓晖.宫颈病变患者病灶组织miR-21、miR-146a、miR-224表达与HR-HPV感染、宫颈病变程度的关系.[J].中南医学科学杂志.,2024,(4):661-664.
宫颈病变患者病灶组织miR-21、miR-146a、miR-224表达与HR-HPV感染、宫颈病变程度的关系
Association between the expression of miR-21, miR-146a and miR-224 in lesion tissues of patients with cervical lesions and HR-HPV infection and the degree of cervical lesions
投稿时间:2023-10-12  修订日期:2024-05-20
DOI:10.15972/j.cnki.43-1509/r.2024.04.040
中文关键词:  HR-HPV  宫颈病变  miR-21  miR-146a  miR-224
英文关键词:HR-HPV  cervical lesion  miR-21  miR-146a  miR-224
基金项目:
作者单位E-mail
丁珍珍 沧州市人民医院妇科,河北沧州 061100 e-mail为fqae20230629@163.com 
王丽丽 沧州市人民医院妇科,河北沧州 061100  
闫锡钊 沧州市人民医院妇科,河北沧州 061100  
安凤兰 沧州中西医结合医院放化疗二科,河北沧州 061000  
杨晓晖 沧州医学高等专科学校科技实验中心,河北沧州 061000  
摘要点击次数: 153
全文下载次数: 160
中文摘要:
      目的分析宫颈病变患者病灶组织miR-21、miR-146a、miR-224表达与高危型人乳头状瘤病毒(HR-HPV)感染、宫颈病变程度的关系。 方法选取宫颈病变患者252例,根据宫颈病变程度分为宫颈癌组、低级别鳞状上皮内病变(LSIL)组、高级别鳞状上皮内病变(HSIL)组;根据是否感染HR-HPV分为感染组和非感染组。另选宫颈正常的子宫肌瘤患者84例为对照组。PCR检测各组miR-21、miR-146a和miR-224表达水平,并分析宫颈癌患者临床病理特征与miR-21、miR-146a和miR-224表达的关系。 结果感染组、非感染组miR-224水平高于对照组,感染组miR-224水平高于非感染组,宫颈癌组高于对照组、LSIL组、HSIL组(P<0.05)。低分化、FIGO分期Ⅱb~Ⅲa期、淋巴结转移、HR-HPV感染的宫颈癌患者病灶组织中miR-224高于中高分化、FIGO分期Ⅰb~Ⅱa期、无淋巴结转移及非HR-HPV感染者(P<0.05)。分化程度、HR-HPV感染、FIGO分期、淋巴结转移是影响宫颈病变患者病灶组织miR-224水平的影响因素。 结论宫颈癌组织miR-224表达明显上调,且HR-HPV感染者miR-224表达水平更高;HR-HPV感染、分化程度、FIGO分期、淋巴结转移与宫颈癌组织miR-224表达密切相关。
英文摘要:
      AimTo analyze the association between the expression of miR-21, miR-146a and miR-224 in lesion tissues of patients with cervical lesions and high risk-human papilloma virus (HR-HPV) infection and the degree of cervical lesions. MethodsAccording to the degree of cervical lesions, 252 patients were divided into the cervical cancer group, the low-grade squamous intraepithelial lesion (LSIL) group and the high-grade squamous intraepithelial lesion (HSIL) group. According to the presence or absence of HR-HPV infection, the patients were divided into infection group and non-infection group. Meanwhile, 84 patients with normal cervix and uterine fibroids were selected as the control group. PCR method was used to detect the expression levels of miR-21, miR-146a and miR-224 in each group. The relationship between clinicopathological characteristics of cervical cancer patients and the expression of miR-21, miR-146a and miR-224 was analyzed. ResultsmiR-224 level in the infection group and the non-infection group was higher than that in the control group, and miR-224 level in the infection group was higher than that in the non-infection group. miR-224 level in the cervical cancer group was higher than those in the control group, LSIL group and HSIL group (P<0.05). The expression of miR-224 in lesion tissues of cervical cancer patients with low differentiation, patients at FIGO stage Ⅱb-Ⅲa and patients with lymph node metastasis was higher than that in patients with moderate and high differentiation, patients at FIGO stage Ⅰb-Ⅱa, patients without lymph node metastasis and patients without HR-HPV infection (P<0.05). Differentiation degree, HR-HPV infection, FIGO staging and lymph node metastasis were factors affecting miR-224 level in lesion tissues of patients with cervical lesions. ConclusionThe expression of miR-224 is significantly up-regulated in cervical cancer tissues, and cervical cancer patients with HR-HPV infection have higher miR-224 levels. HR-HPV infection, differentiation degree, FIGO staging and lymph node metastasis are closely related to the expression of miR-224 in cervical cancer tissues.
查看全文  查看/发表评论  下载PDF阅读器
关闭
function PdfOpen(url){ var win="toolbar=no,location=no,directories=no,status=yes,menubar=yes,scrollbars=yes,resizable=yes"; window.open(url,"",win); } function openWin(url,w,h){ var win="toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=no,width=" + w + ",height=" + h; controlWindow=window.open(url,"",win); } &et=C419C22801107D7A1455BA1A6956A52B0C40E52585E99BD4160A51ECF6AC4D89070A7C54D11423732BE2950A314B6D45263843B24B22AB4B33C4833AC87563558E2465155B41D518CC82C9A271A10DDEA6956720E195A5A493E848C798903E46444299BB75EB08850028D815BEA6F8F0E3B8449B9ADC1B977C0A54E81AB2557C4D6CA380193C59772B082706DC65EA1BB1760D71F7E60447048B7EB1B8C77D36CEE9CBCE8C73360622E37D0A43F4E2DB&pcid=A9DB1C13C87CE289EA38239A9433C9DC&cid=BB33F1C95224820A&jid=6A20DF2A798996E24F064D5ECF83A153&yid=B80136CCD8DCBAA1&aid=&vid=&iid=E158A972A605785F&sid=8DDBA6455F2E3ECF&eid=66D0A4667FE1A38D&fileno=20240440&flag=1&is_more=0">